0 RESTORE-1: first patient dosed with gene therapy in Parkinson’s trial
Voyager Therapeutics has announced the first patient dosed in RESTORE-1, a Phase II trial of VY-AADC gene therapy for the treatment of Parkinson’s disease.
Browsing: Movement disorders
0 BrainStorm scraps initial access to NurOwn® for amyotrophic lateral sclerosis
After careful evaluation of the ‘Right to Try ‘Act, BrainStorm have announced that it will not make NurOwn® available under this legislation at this time.
0 Parkinson’s drugs may cause impulse control disorders
Dopamine agonists and prodrugs taken to treat Parkinson’s disease may cause impulse control disorders in over half the patients they are prescribed to.
0 Is there a link between diabetes and Parkinson’s disease?
According to a large study, individuals with Type 2 diabetes may have an increased risk of being diagnosed with Parkinson’s disease later in life.
0 Multiple sclerosis: new UK guidelines on disease-modifying therapies
The National Institute for Health and Care Excellence (NICE) has recommended the use of four out of six disease-modifying therapies in relapsing–remitting multiple sclerosis.
0 AAN 2018: Nerve stimulation device may help relieve essential tremors in the hand
An abstract to be presented by the American Academy of Neurology (CA, USA) reports patients suffering from hand tremors may find relief with a novel, non-invasive nerve stimulation treatment.
0 Study indicates all degrees of concussion may increase the risk of Parkinson’s disease
A recently published study has indicated that all degrees of concussion may increase the risk of developing Parkinson’s disease.
1 Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson’s disease
This research article from Neurodegenerative Disease Management investigates how age and disease duration affects Parkinson’s treatment outcome with levodopa-carbidopa intestinal gel.
0 World Parkinson’s Day: the year so far in Parkinson’s research – a note from the Editor
We bring together Parkinson’s advances from across research and industry from the year so far.
0 ALKS 5461 receives refusal-to-file for depression: industry news round-up
In this week’s round-up, we cover the latest industry news from depression and Parkinson’s disease. Find out more about our selection of the highlights this week.
